Comparison of Clinical Staging and Secondary Staging of Cervical Cancer

Lisheng Huang
Fujian Provincial Maternity and Children's Hospital: Fujian Provincial Maternity and Children's Hospital

Guobing Liu (✉ guobingliu6081@sina.com)
Southern medicine University Nanfang Hospital

Beihong Zheng
Fujian Provincial Maternity and Children's Hospital

Guang Li
The Third Affiliated Hospital of Southern Medical University

Hui Wang
Southern Medical University

Research

Keywords: cervical cancer, recurrence or uncontrolled, FIGO clinical staging, second postoperative staging

DOI: https://doi.org/10.21203/rs.3.rs-146983/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Objective

To compare the coincidence rate, lymph node metastasis rate, recurrence or uncontrolled rate between the FIGO clinical staging of cervical cancer and the second postoperative staging.

Methods

A retrospective analysis of 999 cervical cancer patients diagnosed and treated in Nanfang Hospital from January 2003 to December 2016 to compare two staging methods through SPSS. Results: There is a significant statistical difference between the results of two stages (P<0.01). Meanwhile the consistency is poor (Kappa value = 0.248 ). There is a significant statistical difference between the number of lymphatic metastases in the two stages (P<0.01). Meanwhile the number of lymphatic metastases in the two stages are related (P<0.01), but the consistency is poor (Kappa value = 0.102). Lymph node metastasis rate with different FIGO staging are different (P<0.01). Lymph node metastasis rate with different postoperative secondary staging are different (P<0.01). There is a significant statistical difference in the number of recurrences or uncontrolled between the two stages (P<0.01). There is a correlation in the recurrences or uncontrolled number between the two stages (P<0.01), consistent poor (Kappa value = 0.252). Different FIGO stagings have different recurrence or uncontrolled rates (P<0.01), and different postoperative secondary stagings have different recurrence or uncontrolled rates (P<0.01).

Conclusion

There are differences in the coincidence rate, lymph node metastasis rate, recurrence or uncontrolled rate between the two stages. The FIGO staging of cervical cancer needs further improvement.

Background

Cervical cancer is the fourth common malignant tumor in women in the world, and the second common malignant tumor in the female reproductive system. Its incidence is higher in developing countries, and it is a common cause of cancer death in developing countries[1]. In 2018, there were approximately 570,000 new cases of cervical cancer worldwide, and more than 310,000 deaths[1-5]. The staging of cervical cancer is of great significance to its treatment. At present, the staging standard of the Federation International of Gynecology and Obstetrics (FIGO) is widely adopted internationally [6-8]. However, the accuracy of FIGO staging has been questioned. There are datas showing that surgical pathology assessment improves the accuracy of early cervical cancer staging, and the FIGO definition of early cervical cancer needs to be improved [9, 10]. This study compared the preoperative clinical FIGO staging and postoperative secondary staging of cervical cancer through a retrospective study, and compared the accuracy o to provide a basis for the optimization of staging methods.

Materials And Methods

General Information

Participants: Selected from January 2003 to December 2016 in the Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, patients with complete clinical data and histopathology of cervical squamous cell carcinoma met the inclusion criteria and excluded. After meeting the criteria, a total of 999 patients
were collected as research objects. Among them, there were 121 patients with stage IA cervical squamous cell carcinoma, 512 patients with stage IB cervical squamous cell carcinoma, 253 patients with stage IIA cervical squamous cell carcinoma, and 113 patients with stage IIB cervical squamous cell carcinoma.

Inclusion criteria: Squamous cell carcinoma of the cervix was diagnosed in our hospital based on the patient's symptoms, signs and auxiliary examinations; Squamous cell carcinoma of the cervix was confirmed by pathology after surgery; The stage was judged to be cervical squamous cell carcinoma according to FIGO staging; Receive surgical treatment in our hospital without adjuvant radiotherapy or chemotherapy or radiochemotherapy before surgery. Perioperative treatment and surgical selection according to the FIGO Guidelines for Diagnosis and Treatment of Gynecological Malignancies.

Research methods

We staged according to the FIGO clinical staging standards. After the operation, all the surgically removed tissues will be sent to the pathology department for examination. Whether gross specimens or pathological sections, at least two deputy chief physicians of the pathology department in our hospital would confirm the pathological results. Then accuracy range of tumor lesions given by the pathological results, was referred to the FIGO guidelines, so we obtained the second postoperative staging. The treatment plan of cervical cancer patients diagnosed and treated in our hospital was determined by the doctors at or above the level of deputy director of the department of gynecology in our hospital according to the FIGO Guidelines. The follow-up plan for the study subjects was also implemented in accordance with the guidelines, and the deadline for follow-up was the patient's tumor recurrence or uncontrolled or December 2018.

By comparing the correlation between FIGO staging and postoperative secondary staging, the rate of lymph node metastasis, recurrence or uncontrolled between two stages, we explored the significance of FIGO staging and postoperative secondary staging.

Statistical methods

All calculation results are sorted and analyzed using IBM SPSS20.0 software. Test level $\alpha=0.05$. When $P<0.05$, the difference is considered to be statistical, and when $P<0.01$, the difference is statistically significant.

Results

Comparison of FIGO staging and postoperative staging

This study separately recorded the staging results of each patient with cervical squamous cell carcinoma before surgery according to the FIGO staging and the results of the second postoperative staging of each patient based on postoperative pathology. In FIGO staging, there were 121 patients in stage IA, 512 in stage IB, 253 in stage IIA, and 113 in stage IIB. In the second stage, there were 249 patients with stage IA, 673 patients with stage IB, 53 patients with stage IIA, and 24 patients with stage IIB. According to the chi-square test comparing the results of FIGO staging and postoperative secondary staging, it is concluded that McNemar$\chi^2$ test $P\approx0.000<0.01$, so there is a significant statistical difference between the results of FIGO staging and postoperative secondary staging; Pearson$\chi^2 = 383.705$, $P\approx0.000<0.01$, so the FIGO staging is related to the second postoperative staging. The Kappa value is 0.248, which is poor. The overall coincidence rate between clinical staging and postoperative secondary staging was 54.25%. In phase IA, there were 106 people matching the two stages, with a compliance
rate of 87.60%. In Phase IB, there were 390 people matching the two stages, with a compliance rate of 76.17%. In phase IIA, 35 people were matching the two stages, with a compliance rate of 13.83%. There are 11 people who match the two stages of Phase II B, and the match rate is 9.73%. Therefore, as the staging increases, the matching rate of the two stagings gradually decreases. Seen in Table 1.

Analysis of the correlation of lymph node metastasis between FIGO staging, postoperative secondary staging

According to the chi-square test comparing the number of lymphatic metastases between FIGO staging and the second postoperative staging, McNemar\(\chi^2\) test \(P \approx 0.000 < 0.01\), so there is a significantly statistical difference in the number of lymphatic metastases between FIGO staging and postoperative second staging. Pearson\(\chi^2\)=58.905, \(P \approx 0.000 < 0.01\), so the number of lymphatic metastases in the FIGO staging and the second postoperative staging were related. Kappa value=0.102, the consistency is poor. According to the chi-square test to calculate the lymph node metastasis rate of different FIGO stages, Pearson\(\chi^2\)=73.493, \(P \approx 0.000 < 0.01\), the results showed that different FIGO stages and lymph node metastasis rates were different. According to the Fisher probability method, the lymph node metastasis rate of different postoperative secondary stages was calculated to obtain \(P \approx 0.000 < 0.01\), and the results showed that different postoperative secondary stages and lymph node metastasis rates were different. In FIGO staging, the number of patients with lymph node metastasis in stage IA was 2 and the rate of lymph node metastasis was 1.65%. The number of patients with lymph node metastasis in stage IB was 56 and the rate of lymph node metastasis was 10.94%. The number of patients in stage IB that showed lymph node metastasis was 62. The lymph node metastasis rate was 24.51%; the number of patients with lymph node metastasis in stage IIB was 40, and the lymph node metastasis rate was 35.40%. In the second postoperative stage, the number of patients with lymph node metastasis in stage IA was 6 and the rate of lymph node metastasis was 2.41%. The number of patients in stage IB with lymph node metastasis was 125, and the rate of lymph node metastasis was 18.57%. The number of patients in stage IIB showed lymph node metastasis patients were 15, and the lymph node metastasis rate was 28.30%. The number of patients with lymph node metastasis in stage IIB was 14 patients, and the lymph node metastasis rate was 58.33%. The number of lymph node metastases in different FIGO stages and surgical pathological stages is shown in the table below. It can be seen that whether it is the FIGO staging or the second postoperative staging, as the staging increases, the rate of lymph node metastasis increases. See Table 2.

Analysis of the correlation of recurrence or uncontrolled between FIGO staging and postoperative change staging

Uncontrolled after surgery means that the tumor continues to exist within the scope of surgical resection included in the radical operation, or the tumor reappears locally within 1 year after the initial operation. Postoperative recurrence means that all tumors seen during the operation have been removed and pathology suggested that there was no tumor at the margin of the surgical specimen, but a tumor appears again 1 year after the operation [11]. According to the chi-square test comparing the number of recurrences or uncontrolled in FIGO staging and the second postoperative staging, it was concluded that McNemar\(\chi^2\) test \(P \approx 0.000 < 0.01\), so the recurrence or uncontrolled number of FIGO staging and postoperative second staging was significant. Pearson\(\chi^2\)=54.433, \(P \approx 0.000 < 0.01\), so the number of recurrences or uncontrolled in the FIGO staging is related to the secondary staging, and the Kappa value=0.252, which showed poor consistency. According to the chi-square test to calculate the recurrence or uncontrolled rate of different FIGO stages, Pearson\(\chi^2\)=36.120, \(P \approx 0.000 < 0.01\), the results showed that different FIGO stages had different recurrence or uncontrolled rates. According to the Fisher probability method, the recurrence or uncontrolled rate of different postoperative stages was calculated to obtain \(P \approx 0.000 < 0.01\), and the results showed that the recurrence or uncontrolled rate of different postoperative stages was
different. In FIGO staging, 6 persons had recurrence or uncontrolled recurrence in stage IA, with a recurrence or uncontrolled rate of 4.96%; 55 persons had recurred or uncontrolled in stage IB, and had a recurrence or uncontrolled rate of 10.74%. The recurrence or uncontrolled people in stage IIA were 30, and the recurrence or uncontrolled rate was 11.86%. The number of relapsed or uncontrolled stage II B was 32, and the recurrence or uncontrolled rate was 28.32%. In the second postoperative stage, the number of relapsed or uncontrolled stage IA was 14 people, and the recurrence or uncontrolled rate was 5.62%. The number of relapsed or uncontrolled stage IB was 89, and the recurrence or uncontrolled rate was 13.22%. The recurrence or uncontrolled rate of stage IIA was 13.22%. The number of uncontrolled persons was 14 people, and the recurrence or uncontrolled rate was 26.42%. The number of relapsed or uncontrolled persons in stage II B was 6 persons, and the recurrence or uncontrolled rate was 25.00%. The recurrence or uncontrolled rates of different FIGO stages and postoperative second stages are shown in the table below. It can be seen that whether it is the FIGO staging or the second postoperative staging, as the staging increased, the recurrence or uncontrolled rate increased. See Table 3.

Conclusion

Among the common tumors in gynecology, such as ovarian cancer and endometrial cancer, mainly adopt pathological staging, and cervical cancer is the only tumor that adopts clinical staging. Accurate staging is an important factor that affects the clinical treatment plan and the evaluation of the prognosis of cervical cancer. At present, the internationally universal standard for clinical staging of cervical cancer is formulated by the International Federation of Gynecology and Obstetrics (FIGO) [12-13]. It can be seen from the source that the first version of cervical cancer The clinical staging was drafted and written by the expert group of the Radiotherapy Committee in 1929, and gradually improved into the latest FIGO staging in 2018 [14]. The birth of the initial clinical staging of cervical cancer was to establish a unified diagnostic standard for evaluating the effects of comparative treatment, and it can also be used to evaluate the prognosis of patients. Before 1999, the main treatment for cervical cancer was radiotherapy [15, 16], and there would be no pathological staging. However, as surgical techniques improve, surgery becomes one of the main treatments [17, 18]. FIGO staging is based on clinical examination results to obtain a pre-treatment staging, which can provide a reference basis for clinicians’ diagnosis and treatment judgments. It is mainly based on clinicians’ examination judgments. It is highly subjective, but the FIGO staging clearly states that the staging has been determined before surgery cannot be changed, even if it is a pathological result. Previous research results have shown that after surgical exploration, some patients found occult metastases in the pelvis, abdominal aorta, parauterine tissue, omentum, and peritoneal lymph nodes based on postoperative pathology [11]. It is obviously that the clinical staging of cervical cancer is less appropriate in this age of surgery; especially its regulation that it can’t be altered by pathology after surgery.

The results of this study showed that there was a positive correlation between preoperative FIGO staging and postoperative staging, and there is a significant difference between clinical staging and postoperative staging. As the staging increased, the matching rate of the two staging gradually decreased and was inversely proportional. In addition, on the mismatch between the two stages: a total underestimation of the FIGO stage was 3.60%. And in the proportion of IA stage assessment was as low as 12.40%, and supplementary treatment was required after surgery. The preoperative clinical stage of some patients is overestimation, and the stage could be reduced according to postoperative pathology. So the FIGO staging obtained before surgery is not accurate and cannot be changed, which is unreasonable. In addition, from the perspective of biopsychosocial medicine model, for patients with postoperative pathological indicated that the FIGO stage was overestimation, maintaining the preoperative staging results would increase the patient's psychological burden and affected the evaluation of the patient's
prognosis. In addition, this article showed that whether it was the FIGO staging or the second postoperative staging, as the staging increased, the rate of lymph node metastasis and the rate of recurrence or uncontrolled increased. Among them, the preoperative and postoperative staging, lymph node metastasis rate and recurrence or uncontrolled were related, but the consistency was poor. The second postoperative staging, FIGO staging of cervical cancer had undergone surgical pathological reassessment, showed the prognosis was different. Therefore, the clinical staging of cervical cancer needed to be further improved. It had certain clinical significance to change the preoperative staging after surgery.

**Declarations**

**Ethics approval and consent to participate:** We have obtained the Ethics Committee approval and the number was NFEC-2020-076.

**Consent for publication:** Not applicable.

**Availability of data and materials:** All data generated or analysed during this study are included in this published article.

**Competing interests:** The authors declare that they have no competing interests.

**Funding:** The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

**Authors’ contributions:**

Lisheng Huang: Data Collection, Manuscript writing

Guobing Liu: Project development

Beihong Zheng: Project development

Guang Li: Manuscript writing

Hui Wang: Data collection

**Acknowledgements:** Not applicable.

**Authors’ information:**

Lisheng Huang: First author, Fujian Provincial Maternity and Children's Hospital

Email: 875624954@qq.com

Guobing Liu: Corresponding author, Southern medicine University Nanfang Hospital
Email:guobingliu6081@sina.com
Beihong Zheng,Fujian Provincial Maternity and Children's Hospital
Email:ptzbh@163.com
Guang Li,The third affiliated hospital of southern medical university
Email:lig2017@163.com
Hui Wang,Southern medicine University
Email:2723780009@qq.com

References

[1] La T, F B, RI S, J F, J L, A J, Cancer Constitutes An Enormous Burden On Society In More And Less Economically Developed Countries Alike. The Occurrence Of Cancer Is Increasing Because Of The Growth And Aging Of The Population A W A A, Breast Cancer Remains The Leading Cause Of Cancer Death Among Females In Less Developed Countries. Other Leading Causes Of Cancer Death In More Developed Countries Include Colorectal Cancer Among Males And Females And Prostate Cancer Among Males. In Less Developed Countries L A S C. CA: a cancer journal for clinicians, 2015, 65(2):87-108.

[2] Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health 2019; 8: e191–203.

[3] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. doi:10.3322/ caac.21492

[4] Lemp Julia M,De Neve Jan-Walter,Bussmann Hermann et al. Lifetime Prevalence of Cervical Cancer Screening in 55 Low- and Middle-Income Countries.[J] .JAMA, 2020, 324: 1532-1542.

[5] Chen W, Sun K, et al. Cancer incidence and mortality in China, 2014. Chin J Cancer Res 2018;30(1):1-12

[6] Benedet JL, Bender H, Jones H III, et al: FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers: FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 70:209-262, 2000

[7] International Federation of Gynecology and Obstetrics: 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 95:S1-257, 2006 (suppl 1)

[8] Monk Bradley J,Tewari Krishnansu S,Koh Wui-Jin,Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions.[J] .J Clin Oncol, 2007, 25: 2952-65.

[9] Petignat Patrick,Loubeyre Pierre,Should we modify the current FIGO staging system for early-stage cervical cancer?[J] .Expert Rev Anticancer Ther, 2008, 8: 1015-7.
[10] Ackermann Sven, Beckmann Matthias W. Accuracy of cervical cancer staging needs improvement. [J]. Am J Obstet Gynecol, 2005, 192: 659; author reply 660.

[11] Lian Lijuan. Lin Qiaozhi Gynecological Oncology [M]. 3rd edition. Beijing: People's Medical Publishing House, 2000. 311-314.

[12] Ruirui Sun, Niyazi Huexidan, Huarong Zhao, Lei Zhang, Yiming Reheman, Yongxing Bao. Journal of Clinical Oncology, 2015, (8): 704-708.

[13] Xiao-Lei Zhang, Juan Peng, Jian-Hua Zheng. International Journal of Reproductive Health/Family Planning, 2011, 30(2): 153-154.

[14] Wang Tong (Tong Wang), Wu Yumei (Yumei WU). China Medical Herald, 2017, 14(24): 46-49.5 Analysis of the difference between FIGO staging and surgical pathological staging of early cervical cancer. Chinese modern doctors August 2017 Volume 55 Number 22

[15] Shrivastava S, Mahantshetty U, Engineer R, Tongaonkar H, Kulkarni J, Dinshaw K. Treatment and outcome in cancer cervix patients treated between 1979 and 1994: a single institutional experience. J Cancer Res Ther. 2013;9(4):672-679.

[16] Shrivastava Shyamkishore, Mahantshetty Umesh, Engineer Reena et al. Cisplatin Chemoradiotherapy vs Radiotherapy in FIGO Stage IIIB Squamous Cell Carcinoma of the Uterine Cervix: A Randomized Clinical Trial. [J] JAMA Oncol, 2018, 4: 506-513.

[17] Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet 2019; 393: 169–82

[18] Höckel Michael, Wolf Benjamin, Schmidt Katja et al. Surgical resection based on ontogenetic cancer field theory for cervical cancer: mature results from a single-centre, prospective, observational, cohort study. [J] Lancet Oncol, 2019, 20: 1316-1326.

Tables

Table 1 Comparison of FIGO staging and second postoperative staging

| Preoperative staging | Preoperative staging | Number of patients in stage IA after operation | Number of patients in stage IB after operation | Number of patients in stage IIA after operation | Number of patients in stage IIB after operation | Number of people in accordance with the stage | Coincidence rate of stages |
|----------------------|----------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|---------------------------|
| Phase IA             | 121                  | 106                                           | 14                                            | 1                                             | 0                                             | 106                                           | 87.60%                    |
| Stage IB             | 512                  | 110                                           | 390                                           | 8                                             | 4                                             | 390                                           | 76.17%                    |
| Stage IIA            | 253                  | 22                                            | 187                                           | 35                                            | 9                                             | 35                                            | 13.83%                    |
| Stage IIB            | 113                  | 11                                            | 82                                            | 9                                             | 11                                            | 11                                            | 9.73%                     |
| the sum              | 999                  | 249                                           | 673                                           | 53                                            | 24                                            | 542                                           | 54.25%                    |
### Table 2: Analysis of the correlation between FIGO staging, secondary staging and lymph node metastasis

| Preoperative by stages | Preoperative staging | After operation | After operation | After operation | After operation | After operation |
|------------------------|----------------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|                        | lymph gland transfer | Phase IA        | lymph gland     | Number of people transferred | Stage IB        | lymph gland     | Number of people transferred | Stage IIA        | lymph gland     | Number of people transferred | Stage IIB        | lymph gland     | Number of people transferred |
| Phase IA               |                      | 2               | 0               | 0               | 0               | 0               |
| Stage IB               | 56                   | 2               | 49              | 3               | 2               |
| Stage IIA              | 62                   | 2               | 47              | 7               | 6               |
| Stage IIB              | 40                   | 0               | 29              | 5               | 6               |
| the sum                | 160                  | 6               | 125             | 15              | 14              |

### Table 3: Analysis of the correlation of recurrence or uncontrolled between FIGO staging and postoperative change staging

| Preoperative by stages | Preoperative staging | After operation | After operation | After operation | After operation |
|------------------------|----------------------|-----------------|-----------------|-----------------|-----------------|
|                        | Recurrence or Not controlled | Phase IA        | Recurrence or Not controlled | Number of people transferred | Stage IB        | Recurrence or Not controlled | Number of people transferred | Stage IIA        | Recurrence or Not controlled | Number of people transferred | Stage IIB        | Recurrence or Not controlled | Number of people transferred |
| Phase IA               | 6                    | 5               | 1               | 0               | 0               |
| Stage IB               | 55                   | 6               | 47              | 2               | 0               |
| Stage IIA              | 30                   | 1               | 20              | 8               | 1               |
| Stage IIB              | 32                   | 2               | 21              | 4               | 5               |
| the sum                | 123                  | 14              | 89              | 14              | 6               |